Akebia Therapeutics Inc
AKBA
查看详细走势图
1.312USD
-0.078-5.60%
交易中 （美东）报价延迟15分钟
23.99M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.60%
5天
-7.60%
1月
+0.16%
6月
-51.58%
今年开始到现在
-18.50%
1年
-31.30%
查看详细走势图
TradingKey Akebia Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Akebia Therapeutics Inc当前公司基本面数据相对健康，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在药品行业排名74/157位。机构持股占比非常高，近一月多位分析师给出公司评级为强力买入。最高目标价4.40。中期看，股价处于下降通道。近一个月，市场表现较强，技术面和基本面综合得分较高，较强的走势得到基本面和技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Akebia Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看空
Akebia Therapeutics Inc亮点
亮点风险
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
业绩高增长
公司营业收入稳步增长，连续3年增长21.36%
估值低估
公司最新PE估值-64.49，处于3年历史低位
机构加仓
最新机构持股132.23M股，环比增加1.10%
乔尔·格林布拉特持仓
明星投资者乔尔·格林布拉特持仓，最新持仓市值15.97K
分析师目标
根据
5
位分析师
强力买入
评级
4.400
目标均价
+216.55%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Akebia Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Akebia Therapeutics Inc简介
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with two commercial products for patients impacted by kidney disease. The Company is focused on developing and commercializing therapeutics. Its two preclinical development candidates are AKB-9090 and AKB-10108. The Company’s portfolio and hypoxia-inducible factor (HIF)-based commercialized products include Auryxia (ferric citrate) and Vafseo. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo, an oral HIF prolyl hydroxylase (HIF-PH), inhibitor. It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.
公司代码AKBA
公司Akebia Therapeutics Inc
CEOButler (John P)
网址https://akebia.com/
相关品种
